Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01260571|
Recruitment Status : Unknown
Verified September 2010 by Zurita Laboratorio Farmaceutico Ltda..
Recruitment status was: Not yet recruiting
First Posted : December 15, 2010
Last Update Posted : December 15, 2010
Sixty two subjects will take part in this study. The study is unic arm. The subjects used the product once and will be evaluated in the regression of pimples in the times 0,4,6,8 and 24 hours after application.
A follow-up visit will be made 24 hours after initiation of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Treatment of Acne Vulgaris Grade II in a Short Period of Time.||Drug: Benzoyl peroxide and sulfur||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||62 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||March 2011|
|Estimated Study Completion Date :||March 2011|
Experimental: Benzoyl Peroxide and Sulfur
Topical Medications containing benzoyl peroxide and sulfur
Drug: Benzoyl peroxide and sulfur
topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
- Clinical study to evaluate the efficacy of topical medications containing benzoyl peroxide and sulfur in the regression in the short time (24 hours) of moderate acne vulgaris grade II (pimples). [ Time Frame: 24 hours ]Clinical evolution of the target lesions for each experimental time regarding the parameters of reddening, size and general appearance of the lesion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01260571
|Contact: Sergio Schalka, Doctor's||(11) email@example.com|
|Medcin Instituto da Pele|
|Osasco, São Paulo, Brazil, 06023-000|
|Contact: Sergio Schalka, Doctor's (11) 36816362 firstname.lastname@example.org|
|Principal Investigator: Sergio Schalka, Doctor's|